Macrophage-delivered drugs for solid tumors
Raised to date
$2.9M
of $4M offered across 2 Form D filings
Resolute Science, Inc. is a biotechnology company dedicated to advancing cancer treatment through innovative therapeutic strategies. The company specializes in addressing the challenges of solid tumor cancers, with a focus on overcoming recurrence and drug resistance.
Resolute Science stands out with their MAC-TAC platform, which leverages Tumor-Associated Macrophages to deliver cytotoxic payloads, a method distinct from conventional cancer cell targeting.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Apr 3, 2026 | Security to be acquired | $2.9M/ $4M | Form D/A |
| Feb 10, 2025 | Security to be acquired | $1.4M/ $3M | Form D |
Cancer Therapeutics
The MAC-TAC platform is a groundbreaking technology in cancer therapeutics, specifically designed to harness Tumor-Associated Macrophages. These macrophages are used to transport cytotoxic agents directly to tumors, providing a targeted, robust attack on cancer cells.
Built for
Patients with solid tumor cancers
